{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:31:14Z","timestamp":1790886674116,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondazione AIRC","award":["IG 2018 \u2013ID. 21354"],"award-info":[{"award-number":["IG 2018 \u2013ID. 21354"]}]},{"name":"5 per Mille 2019","award":["ID. 22759"],"award-info":[{"award-number":["ID. 22759"]}]},{"name":"5 per Mille 2019","award":["BIOV19ROSATO"],"award-info":[{"award-number":["BIOV19ROSATO"]}]},{"name":"Ministry of Health-Alliance Against Cancer","award":["RCR-2019-23669115"],"award-info":[{"award-number":["RCR-2019-23669115"]}]},{"name":"Ministry of Health-Alliance Against Cancer","award":["WG6-ACC-2020"],"award-info":[{"award-number":["WG6-ACC-2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Uveal melanoma (UM) represents the most common primary intra-ocular malignancy in adults. Up to 50% of the patients develop distant metastases within 10\u2009years from diagnosis, with the liver as the most common site. Upon metastatization, life expectancy strongly reduces and immune checkpoint inhibitors that prove effective in cutaneous melanoma do not modify clinical outcome. To date, few studies have focused on deciphering the immunomodulatory features of metastatic UM microenvironment, and there are no prognostic models for clinical use. This highlights the urgent need to understand the delicate interplay between tumor and immune cells acting at the site of metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected a patient cohort comprising 21 metastatic UM patients. Hepatic and extra-hepatic UM metastasis samples were studied by multiplex immunofluorescence to assess the tumor immune cell composition. Quantitative analyses were performed to correlate immune cell densities with treatment response, metastasis site and patient survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared to patients with progressive disease, those with controlled disease had a higher intra-tumoral\/peritumoral ratio of CD8\u2009+\u2009Granzyme B+ cells, higher density of intra-tumoral CD8+ cytotoxic T lymphocytes (CTL) and an increased percentage of UM cells in close proximity to T lymphocytes, reflecting a role of tumor-killing T cells in the disease. In liver metastases (LM), the intra-tumoral densities of CD163+ tumor-associated macrophages (TAM) and of total CD8+ T cells were higher than in extra-hepatic UM metastases, but the percentage of Granzyme B+ CTL was lower. Moreover, LM displayed more UM cells adjacent to both CTL and TAM, and also more T cells in proximity to TAM, all signs of an impaired immune response. The percentage of activated CTL within the tumor represented a prognostic indicator, as patients with a higher intra-tumoral percentage of CD8\u2009+\u2009Granzyme B+ cells had the better outcome. A temptative Immunoscore was generated and proved capable to stratify patients with improved survival. Finally, CD4\u2009+\u2009FoxP3+ T cells appeared a crucial population for response to immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results of this study underly the clinical relevance and functional importance of composition and localization of antitumor effector cells for the progression of UM metastasis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-021-01947-1","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T17:02:56Z","timestamp":1620147776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The immune cell landscape of metastatic uveal melanoma correlates with overall survival"],"prefix":"10.1186","volume":"40","author":[{"given":"Anna","family":"Tosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Cappellesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Paolo","family":"Dei Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Pigozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Fabozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sbaraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Blandamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-8386","authenticated-orcid":false,"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"issue":"1","key":"1947_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38\u201344. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309034.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1947_CR2","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.18632\/oncotarget.6614","volume":"7","author":"P Johansson","year":"2016","unstructured":"Johansson P, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7(4):4624\u201331. https:\/\/doi.org\/10.18632\/oncotarget.6614.","journal-title":"Oncotarget"},{"issue":"7","key":"1947_CR3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044.","journal-title":"Cell"},{"issue":"2","key":"1947_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/modpathol.2013.138","volume":"27","author":"KG Griewank","year":"2014","unstructured":"Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol. 2014;27(2):175\u201383. https:\/\/doi.org\/10.1038\/modpathol.2013.138.","journal-title":"Mod Pathol"},{"issue":"9","key":"1947_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.040.","journal-title":"Ophthalmology"},{"issue":"5","key":"1947_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","volume":"119","author":"JKV Willson","year":"2001","unstructured":"Willson JKV, et al. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15. Arch Ophthalmol. 2001;119(5):670\u20136. https:\/\/doi.org\/10.1001\/archopht.119.5.670.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1947_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2214\/ajr.157.6.1950883","volume":"157","author":"JG Lorigan","year":"1991","unstructured":"Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. Am J Roentgenol. 1991;157(6):1279\u201381. https:\/\/doi.org\/10.2214\/ajr.157.6.1950883.","journal-title":"Am J Roentgenol"},{"issue":"7","key":"1947_CR8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, et al. Prognosis of mucosal, Uveal, Acral, Nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist. 2016;21(7):848\u201354. https:\/\/doi.org\/10.1634\/theoncologist.2015-0522.","journal-title":"Oncologist"},{"key":"1947_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","volume":"11","author":"BA Krantz","year":"2017","unstructured":"Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11. Dove Medical Press Ltd:279\u201389. https:\/\/doi.org\/10.2147\/OPTH.S89591.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"1947_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","volume":"98","author":"ES Gragoudas","year":"1991","unstructured":"Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patents with metastases from Uveal melanoma. Ophthalmology. 1991;98(3):383\u201390. https:\/\/doi.org\/10.1016\/S0161-6420(91)32285-1.","journal-title":"Ophthalmology"},{"issue":"1","key":"1947_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cncr.11872","volume":"100","author":"EC Hsueh","year":"2004","unstructured":"Hsueh EC, Essner R, Foshag LJ, Ye X, Wang H-J, Morton DL. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100(1):122\u20139. https:\/\/doi.org\/10.1002\/cncr.11872.","journal-title":"Cancer"},{"issue":"6","key":"1947_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cncr.28480","volume":"120","author":"SS Agarwala","year":"2014","unstructured":"Agarwala SS, Eggermont AMM, O\u2019Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120(6):781\u20139. https:\/\/doi.org\/10.1002\/cncr.28480.","journal-title":"Cancer"},{"issue":"15","key":"1947_CR13","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/cncr.29727","volume":"122","author":"C Chattopadhyay","year":"2016","unstructured":"Chattopadhyay C, et al. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016;122(15) John Wiley and Sons Inc:2299\u2013312. https:\/\/doi.org\/10.1002\/cncr.29727.","journal-title":"Cancer"},{"issue":"2","key":"1947_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.17925\/OHR.2017.13.02.100","volume":"13","author":"EN Kinsey","year":"2017","unstructured":"Kinsey EN, Salama AKS. Metastatic uveal melanoma-A review of current therapies and future directions. Eur Oncol Haematol. 2017;13(2) Touch Briefings:100\u20136. https:\/\/doi.org\/10.17925\/OHR.2017.13.02.100.","journal-title":"Eur Oncol Haematol"},{"issue":"1","key":"1947_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","volume":"61","author":"R Danielli","year":"2012","unstructured":"Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61(1):41\u20138. https:\/\/doi.org\/10.1007\/s00262-011-1089-0.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1947_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","volume":"7","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7(1):299. https:\/\/doi.org\/10.1186\/s40425-019-0800-0.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1947_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-Centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18(6):792\u2013802. https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1947_CR18","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","volume":"119","author":"MD Onken","year":"2012","unstructured":"Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596\u2013603. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.017.","journal-title":"Ophthalmology"},{"issue":"5","key":"1947_CR19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22(5):1234\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2071.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1947_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJM Gooden","year":"2011","unstructured":"Gooden MJM, De Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1) Nature Publishing Group:93\u2013103. https:\/\/doi.org\/10.1038\/bjc.2011.189.","journal-title":"Br J Cancer"},{"issue":"1","key":"1947_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/1097-0142(19900101)65:1<112::AID-CNCR2820650123>3.0.CO;2-X","volume":"65","author":"POL De Cruz","year":"1990","unstructured":"De Cruz POL, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65(1):112\u20135. https:\/\/doi.org\/10.1002\/1097-0142(19900101)65:1<112::AID-CNCR2820650123>3.0.CO;2-X.","journal-title":"Cancer"},{"key":"1947_CR22","unstructured":"\u201cImmunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. | IOVS | ARVO Journals.\u201d https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2161143 (Accessed 01 Oct 2020)."},{"issue":"2","key":"1947_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1167\/iovs.10-5979","volume":"52","author":"IHG Bronkhorst","year":"2011","unstructured":"Bronkhorst IHG, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GPM, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Investig Ophthalmol Vis Sci. 2011;52(2):643\u201350. https:\/\/doi.org\/10.1167\/iovs.10-5979.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1947_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.humpath.2017.06.005","volume":"66","author":"Y Krishna","year":"2017","unstructured":"Krishna Y, McCarthy C, Kalirai H, Coupland SE. Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Hum Pathol. 2017;66:159\u201366. https:\/\/doi.org\/10.1016\/j.humpath.2017.06.005.","journal-title":"Hum Pathol"},{"issue":"9","key":"1947_CR25","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-15-2294","volume":"22","author":"LD Rothermel","year":"2016","unstructured":"Rothermel LD, Sabesan AC, Stephens DJ, Chandran SS, Paria BC, Srivastava AK, et al. Identification of an immunogenic subset of metastatic Uveal melanoma. Clin Cancer Res. 2016;22(9):2237\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2294.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1947_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","volume":"148","author":"JJ Augsburger","year":"2009","unstructured":"Augsburger JJ, Corr\u00eaa ZM, Shaikh AH. Effectiveness of treatments for metastatic Uveal melanoma. Am J Ophthalmol. 2009;148(1):119\u201327. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.023.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"1947_CR27","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. Aug. 2019;30(8):1370\u201380. https:\/\/doi.org\/10.1093\/annonc\/mdz176.","journal-title":"Ann Oncol"},{"issue":"10","key":"1947_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.20517\/2394-4722.2017.39","volume":"3","author":"M Terai","year":"2017","unstructured":"Terai M, Mastrangleo MJ, Sato T. Immunological aspect of the liver and metastatic uveal melanoma. J Cancer Metastasis Treat. 2017;3(10):231. https:\/\/doi.org\/10.20517\/2394-4722.2017.39.","journal-title":"J Cancer Metastasis Treat"},{"key":"1947_CR29","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3389\/fimmu.2020.579894","volume":"11","author":"MG Narducci","year":"2020","unstructured":"Narducci MG, Tosi A, Frezzolini A, Scala E, Passarelli F, Bonmassar L, et al. Reduction of T lymphoma cells and immunological invigoration in a patient concurrently affected by melanoma and Sezary syndrome treated with Nivolumab. Front Immunol. 2020;11:2452. https:\/\/doi.org\/10.3389\/fimmu.2020.579894.","journal-title":"Front Immunol"},{"issue":"2","key":"1947_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1947_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.humpath.2017.09.012","volume":"69","author":"K Wang","year":"2017","unstructured":"Wang K, Shen T, Siegal GP, Wei S. The CD4\/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Hum Pathol. 2017;69:110\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2017.09.012.","journal-title":"Hum Pathol"},{"issue":"1","key":"1947_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cmi.2010.56","volume":"8","author":"W Shah","year":"2011","unstructured":"Shah W, Yan X, Jing L, Zhou Y, Chen H, Wang Y. A reversed CD4\/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol. 2011;8(1):59\u201366. https:\/\/doi.org\/10.1038\/cmi.2010.56.","journal-title":"Cell Mol Immunol"},{"key":"1947_CR33","doi-asserted-by":"publisher","unstructured":"Carstens JL, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8. https:\/\/doi.org\/10.1038\/ncomms15095.","DOI":"10.1038\/ncomms15095"},{"key":"1947_CR34","doi-asserted-by":"publisher","unstructured":"Neubert NJ, et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018;10(436). https:\/\/doi.org\/10.1126\/scitranslmed.aan3311.","DOI":"10.1126\/scitranslmed.aan3311"},{"key":"1947_CR35","doi-asserted-by":"publisher","unstructured":"Basile MS, et al. Immunobiology of uveal melanoma: state of the art and therapeutic targets. Front Oncol. 2019;9. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2019.01145.","DOI":"10.3389\/fonc.2019.01145"},{"issue":"10","key":"1947_CR36","doi-asserted-by":"publisher","first-page":"e947169","DOI":"10.4161\/21624011.2014.947169","volume":"8","author":"PL Triozzi","year":"2019","unstructured":"Triozzi PL, Schoenfield L, Plesec T, Saunthararajah Y, Tubbs RR, Singh AD. Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes. Oncoimmunology. 2019;8(10):e947169. https:\/\/doi.org\/10.4161\/21624011.2014.947169.","journal-title":"Oncoimmunology"},{"key":"1947_CR37","doi-asserted-by":"publisher","unstructured":"Qin Y, et al. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: a pilot study. Oncoimmunology. 2017;6(6). https:\/\/doi.org\/10.1080\/2162402X.2017.1321187.","DOI":"10.1080\/2162402X.2017.1321187"},{"issue":"7","key":"1947_CR38","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R","volume":"89","author":"T Aoyama","year":"2000","unstructured":"Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89(7):1561\u20138. https:\/\/doi.org\/10.1002\/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R.","journal-title":"Cancer"},{"key":"1947_CR39","doi-asserted-by":"publisher","unstructured":"Qin Y, et al. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-000960.","DOI":"10.1136\/jitc-2020-000960"},{"issue":"1","key":"1947_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/cmr.0000000000000701","volume":"31","author":"R Bao","year":"2021","unstructured":"Bao R, Surriga O, Olson DJ, Allred JB, Strand CA, Zha Y, et al. Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Res. Feb. 2021;31(1):27\u201337. https:\/\/doi.org\/10.1097\/cmr.0000000000000701.","journal-title":"Melanoma Res"},{"issue":"4","key":"1947_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u0300s-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245.","journal-title":"Nat Rev Cancer"},{"issue":"7791","key":"1947_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1914-8.","journal-title":"Nature"},{"key":"1947_CR43","doi-asserted-by":"publisher","unstructured":"C. Saut\u00e8s-Fridman, F. Petitprez, J. Calderaro, and W. H. Fridman, \u201cTertiary lymphoid structures in the era of cancer immunotherapy,\u201d Nat Rev Cancer, vol. 19, no. 6. Nature Publishing Group, pp. 307\u2013325, Jun. 01, 2019, doi: https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","DOI":"10.1038\/s41568-019-0144-6"},{"key":"1947_CR44","doi-asserted-by":"publisher","unstructured":"Massi D, et al. The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. J Immunother Cancer. 2019;7(1). https:\/\/doi.org\/10.1186\/s40425-019-0797-4.","DOI":"10.1186\/s40425-019-0797-4"},{"issue":"9","key":"1947_CR45","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1167\/iovs.11-9280","volume":"53","author":"IHG Bronkhorst","year":"2012","unstructured":"Bronkhorst IHG, Khanh Vu TH, Jordanova ES, Luyten GPM, van der Burg SH, Jager MJ. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Investig Ophthalmol Vis Sci. 2012;53(9):5370\u20138. https:\/\/doi.org\/10.1167\/iovs.11-9280.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"10135","key":"1947_CR46","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)30789-X.","journal-title":"Lancet"},{"issue":"S3","key":"1947_CR47","doi-asserted-by":"publisher","first-page":"P193","DOI":"10.1186\/2051-1426-2-s3-p193","volume":"2","author":"M Capone","year":"2014","unstructured":"Capone M, et al. Immunoscore: a new possible approach for melanoma classification. J Immunother Cancer. Dec. 2014;2(S3):P193. https:\/\/doi.org\/10.1186\/2051-1426-2-s3-p193.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"1947_CR48","doi-asserted-by":"publisher","first-page":"P11","DOI":"10.1186\/1479-5876-12-s1-p11","volume":"12","author":"C Bifulco","year":"2014","unstructured":"Bifulco C, et al. MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab. J Transl Med. 2014;12(Suppl 1):P11. https:\/\/doi.org\/10.1186\/1479-5876-12-s1-p11.","journal-title":"J Transl Med"},{"issue":"2 SUPPL","key":"1947_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.21060","volume":"43","author":"V Racanelli","year":"2006","unstructured":"Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006;43(2 SUPPL):1. https:\/\/doi.org\/10.1002\/hep.21060.","journal-title":"Hepatology"},{"issue":"19","key":"1947_CR50","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","volume":"78","author":"M Yang","year":"2018","unstructured":"Yang M, McKay D, Pollard JW, Lewis CE. Diverse functions of macrophages in different tumor microenvironments. Cancer Res. 2018;78(19) American Association for Cancer Research Inc:5492\u2013503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1367.","journal-title":"Cancer Res"},{"issue":"8","key":"1947_CR51","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2217\/imt-2018-0156","volume":"11","author":"J Kowal","year":"2019","unstructured":"Kowal J, Kornete M, Joyce JA. Re-education of macrophages as a therapeutic strategy in cancer. Immunotherapy. 2019;11(8) Future Medicine Ltd:677\u201389. https:\/\/doi.org\/10.2217\/imt-2018-0156.","journal-title":"Immunotherapy"},{"issue":"21","key":"1947_CR52","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344\u201353. https:\/\/doi.org\/10.1002\/cncr.30258.","journal-title":"Cancer"},{"issue":"16","key":"1947_CR53","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/imt-2017-0066","volume":"9","author":"A Javed","year":"2017","unstructured":"Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017;9(16):1323\u201330. https:\/\/doi.org\/10.2217\/imt-2017-0066.","journal-title":"Immunotherapy"},{"key":"1947_CR54","doi-asserted-by":"publisher","unstructured":"Durante MA, et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11(1). https:\/\/doi.org\/10.1038\/s41467-019-14256-1.","DOI":"10.1038\/s41467-019-14256-1"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-01947-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-01947-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-01947-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T17:03:35Z","timestamp":1620147815000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-01947-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-01947-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by local Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed with submission of the manuscript for publication and agree to be accountable for all aspect of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}